Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis

International Journal of Antimicrobial Agents

Volumn 34, Issue 1, 2009, Pages 67-71

  Fang, Annie F ^a   Palmer, James N ^b   Chiu, Alexander G ^b   Blumer, Jeffrey L ^c   Crownover, Penelope H ^a   Campbell, Michael D ^d   Damle, Bharat D ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Azithromycin extended release; Chronic rhinosinusitis; Pharmacokinetics; Sinus mucosa

Indexed keywords

AZITHROMYCIN;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARANASAL SINUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOSINUSITIS; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHROMATOGRAPHY, LIQUID; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; OLFACTORY MUCOSA; PLASMA; SINUSITIS; YOUNG ADULT;

EID: 67349099518     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.01.014     Document Type: Article

References (11)

1. Blumer J.L. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 26 Suppl. 3 (2005) S143-S147
2. Danesi R., Lucchi M., Pasqualetti G., Giovannetti E., Damle B., Andrews E., et al. Single-dose azithromycin microspheres (AZ-M) achieves improved lung pharmacokinetics versus azithromycin tablets (AZ-IR). Program and Abstracts of the 2006 American Thoracic Society (ATS) International Conference, 19-24 May 2006, San Diego, CA. American Thoracic Society (2006) [Abstract A62]
3. Girard D., Finegan S.M., Dunne M.W., and Lame M.E. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 56 (2005) 365-371
4. Ehnhage A., Rautiainen M., Fang A.F., and Sanchez S.P. Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis. Int J Antimicrob Agents 31 (2008) 561-566
5. Pfizer Inc. Azithromycin [prescribing information]. New York, NY: Pfizer Inc; 2008.
6. Foulds G., Shepard R.M., and Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 Suppl. A (1990) 73-82
7. Karma P., Pukander J., and Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis 10 (1991) 856-859
8. Gladue R.P., Bright G.M., Isaacson R.E., and Newborg M.F. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33 (1989) 277-282
9. Liu P., Allaudeen H., Chandra R., Phillips K., Jungnik A., Breen J.D., et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 51 (2007) 103-109
10. Amsden G.W. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 18 Suppl. 1 (2001) S11-S15
11. Carceles C.M., Fernandez-Varon E., Marin P., and Escudero E. Tissue disposition of azithromycin after intravenous and intramuscular administration to rabbits. Vet J 174 (2007) 154-159